INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of GSK plc investors regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1]. Group 1: Company Developments - On July 17, 2025, GSK announced that the FDA Oncologic Drugs Advisory Committee voted against the overall benefit/risk profile for the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations [3]. - Following this announcement, GSK's American Depositary Receipt (ADR) price decreased by $1.81 per share, representing a 4.73% decline, closing at $36.47 per share on the same day [3]. Group 2: Legal Context - The Pomerantz Firm, known for its expertise in corporate, securities, and antitrust class litigation, is leading the investigation into GSK's practices [4]. - The firm has a long history of fighting for the rights of victims of securities fraud and has successfully recovered multimillion-dollar damages for class members [4].